NEW YORK (GenomeWeb) – Investment bank Mizuho Securities has upgraded shares of Fluidigm from Neutral to Buy citing improved end markets and the expected effects from the firm's recent acquisition of DVS Sciences.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.
This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.